Terns Pharmaceuticals, Inc. Gross Margin

Gross Margin of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending December 31, 2021 was 88.6% (a Infinity% increase compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by Infinity%
  • Annual Gross Margin for 2021 was 48.8% (a Infinity% increase from previous year)
  • Annual Gross Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Gross Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Gross Margin ending December 31, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by NaN% year-over-year
Trailing Gross Margin for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Terns Pharmaceuticals, Inc.

Most recent Gross Marginof TERN including historical data for past 10 years.

Interactive Chart of Gross Margin of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 88.6% 0.0% 0.0% 0.0% 48.8%
2020 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0%
2018 0.0%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.